CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles by Marc Terrones, Christophe Deben, Felicia Rodrigues-Fortes, Anne Schepers, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer

Get full text

Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays by Christophe Deben, Edgar Cardenas De La Hoz, Felicia Rodrigues Fortes, Maxim Le Compte, Sofie Seghers, Steve Vanlanduit, Hendrik Vercammen, Bert Van Den Bogert, Nelson Dusetti, Abraham Lin, Geert Roeyen, Marc Peeters, Hans Prenen, Filip Lardon, Evelien Smits

Get full text

Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer by Maxim Le Compte, Edgar Cardenas De La Hoz, Sofía Peeters, Felicia Rodrigues Fortes, Christophe Hermans, Andreas Domen, Evelien Smits, Filip Lardon, Timon Vandamme, Abraham Lin, Steve Vanlanduit, Geert Roeyen, Steven Van Laere, Hans Prenen, Marc Peeters, Christophe Deben

Get full text

Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition by Christophe Deben, Laurie Freire Boullosa, Felicia Rodrigues Fortes, Edgar Cardenas De La Hoz, Maxim Le Compte, Sofie Seghers, Marc Peeters, Steve Vanlanduit, Abraham Lin, Krijn K. Dijkstra, Paul Van Schil, Jeroen M. H. Hendriks, Hans Prenen, Geert Roeyen, Filip Lardon, Evelien Smits

Get full text